Researchers revive an abandoned depression drug target using structurally novel NK1 receptor inhibitors

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs such as aprepitant…

Continue Reading

News Source: medicalxpress.com